【摘要】：[目的]觀察芳香化酶抑制劑來曲唑?qū)β闶笙贅幽倚园〢CC-LM移植瘤抗腫瘤作用,探討芳香化酶抑制劑抑瘤作用機(jī)制,為臨床治療涎腺腺樣囊性癌提供理論依據(jù)。[方法]構(gòu)建裸鼠腺樣囊性癌移植瘤模型。通過右腋皮下注射1×106個(gè)腺樣囊性癌細(xì)胞,觀察成瘤情況。種瘤兩周后隨機(jī)分為三組,每組8只,分別為對照組(生理鹽水,0.2ml/只/2d)、二甲基亞砜(DMSO)組(DMSO,0.01ml/kg/2d)、來曲唑組(來曲唑,5mg/kg/2d+DMSO,0.01ml/kg/2d)。記錄裸鼠重量變化及瘤體體積,3天/次。種瘤兩周后開始藥物干預(yù),四周時(shí)處死,剝離瘤體,稱重計(jì)算抑瘤率,繪制腫瘤生長曲線。取部分新鮮瘤體組織進(jìn)行流式細(xì)胞術(shù)檢測,比較各組凋亡率差異。部分瘤體組織進(jìn)行伊紅蘇木素染色(HE染色)和芳香化酶p450免疫組織化學(xué)染色,比較各組腫瘤生長狀況及芳香化酶P450在腫瘤細(xì)胞中的表達(dá)。采用SPSS13.0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)分析。[結(jié)果]1.瘤體重量及抑瘤率結(jié)果:對照組、DMSO組、來曲唑組瘤體重量分別為1.50±0.39g、1.52±0.26g、0.65±0.18g。對照組及DMSO組與來曲唑組之間有差別(P0.05),對照組與DMSO組之間無差別(P0.05),來曲唑抑瘤率為56.67%。2.各組腫瘤體積變化:對照組與DMSO組瘤體變化大,而來曲唑組變化較小。對照組及DMSO組與來曲唑組之間有顯著差異(P0.01),差別有統(tǒng)計(jì)學(xué)意義(P0.05);對照組與DMSO組之間差別無統(tǒng)計(jì)學(xué)意義(P0.05)。3.凋亡率結(jié)果:對照組、DMSO組、來曲唑組凋亡率分別為4.6±1.8%、5.7±1.5%、13.6±4.2%,對照組與DMSO組之間差別無統(tǒng)計(jì)學(xué)意義(P0.05),來曲唑與對照組、DMSO組均有顯著性差異(P0.01)。4.灰度值結(jié)果:對照組、DMSO組、來曲唑組的平均灰度值分別為87.75±3.73、88.37±3.85、95.88±4.24。對照組與DMSO組之間差別無統(tǒng)計(jì)學(xué)意義(P0.05),來曲唑與對照組及DMSO組均有顯著性差異(P0.01)。[結(jié)論]1.芳香化酶抑制劑來曲唑能夠抑制裸鼠腺樣囊性癌移植瘤的生長。2.來曲唑能降低裸鼠腺樣囊性癌移植瘤內(nèi)P450的表達(dá)。
[Abstract]:[objective] to observe the antitumor effect of aromatase inhibitor letrozole on ACC-LM xenografts of adenoid cystic carcinoma in nude mice, and to explore the mechanism of aromatase inhibitor inhibiting tumor, and to provide theoretical basis for clinical treatment of salivary adenoid cystic carcinoma. Methods the transplanted tumor model of adenoid cystic carcinoma in nude mice was established. The tumorigenesis was observed by subcutaneous injection of 1 脳 106 adenoid cystic carcinoma cells in the right axilla. After two weeks, they were randomly divided into three groups: control group (normal saline 0.2 ml / rat / 2 d), dimethyl sulfoxide (DMSO) group (DMSO,0.01ml/kg/2d) and letrozole group (letrozole 5 mg / kg / 2 d DMSO,0.01ml/kg/2d). The weight change and tumor volume of nude mice were recorded for 3 days. After two weeks of drug intervention, the tumor was killed, the tumor was stripped, the tumor inhibition rate was calculated, and the tumor growth curve was drawn. Some fresh tumor tissues were detected by flow cytometry to compare the apoptotic rate of each group. Some tumor tissues were stained with eosin (HE) and aromatase p450 immunohistochemical staining to compare the tumor growth status and the expression of aromatase P450 in tumor cells. SPSS13.0 statistical software was used for statistical analysis. [result] 1. Results: the tumor weight and tumor inhibition rate in the control group and letrozole group were 1.50 鹵0.39g / L and 1.52 鹵0.26g/ 0.65 鹵0.18grespectively. There was significant difference between control group and DMSO group and letrozole group (P0.05), but there was no difference between control group and DMSO group (P0.05). The inhibitory rate of letrozole was 56.67.2. The change of tumor volume in control group and DMSO group was larger than that in letrozole group. There was significant difference between control group and DMSO group and letrozole group (P0.01), the difference was statistically significant (P0.05), but there was no significant difference between control group and DMSO group (P0.05). 3. Apoptosis rate: the apoptotic rate of control group and letrozole group were 4.6 鹵1.8 and 5.7 鹵1.5 respectively. There was no significant difference between control group and DMSO group (P0.05). There was significant difference between letrozole group and control group (P0.01). Results: the average gray values of the control group and letrozole group were 87.75 鹵3.73 鹵88.37 鹵3.85 鹵95.88 鹵4.24, respectively. There was no significant difference between control group and DMSO group (P0.05), letrozole was significantly different from control group and DMSO group (P0.01). [conclusion] 1. Letrozole, an aromatase inhibitor, inhibited the growth of xenografts of adenoid cystic carcinoma in nude mice. Letrozole can reduce the expression of P 450 in xenografts of adenoid cystic carcinoma in nude mice.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R739.8

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙誼寧;陶陶;張力杰;陳恕求;姜華;陳明;;雌激素受體ERα及ERβ與腫瘤關(guān)系的研究進(jìn)展[J];東南大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2016年03期

2 王秋銳;楊健;趙華平;張英懷;;雌激素受體及芳香化酶在牙齦癌組織中的表達(dá)和意義[J];牙體牙髓牙周病學(xué)雜志;2015年05期

3 劉一;楊海娟;楊巍;趙立波;方翼;馮婉玉;;細(xì)胞色素P4502A6基因多態(tài)性與來曲唑藥代動力學(xué)和藥效學(xué)的相關(guān)性研究[J];中國臨床藥理學(xué)雜志;2015年06期

4 王溪;王戰(zhàn)建;;雌激素及抗雌激素藥物與甲狀腺癌[J];中華內(nèi)分泌代謝雜志;2014年12期

5 李敏敏;徐明菊;孫萬邦;;生物治療涎腺腺樣囊性癌的研究進(jìn)展[J];國際免疫學(xué)雜志;2014年06期

6 楊堯;陸曉媛;;來曲唑聯(lián)合依維莫斯對人子宮內(nèi)膜癌細(xì)胞的體外抑制作用及機(jī)制[J];山東醫(yī)藥;2014年14期

7 楊欣;薛麗燕;劉宇;郭蕾;溫們;林冬梅;;肺癌組織中雌激素受體α和雌激素受體β的表達(dá)及臨床意義[J];中華腫瘤雜志;2013年09期

8 唐東華;周壽紅;王成昆;劉紅光;;來曲唑增強(qiáng)環(huán)磷酰胺對乳腺癌裸鼠移植瘤生長的抑制作用探討[J];中外醫(yī)療;2012年36期

9 曾子君;趙s沛，

本文編號：2255205